Zhifei Biological Products

Chongqing Zhifei Biological Products Co., Ltd. (Zhifei) has its presence in biological product industry in 2002, and was listed on the Shenzhen Stock Exchange in September 2010, becoming the first privately-run vaccine enterprise listed on ChiNext. With the rapid development in the past 21 years and support of its nearly 6,000 employees, Zhifei Biologics has developed into the leading company and the largest listed Vaccine Company in the People's Republic of China.

As an international high-tech biological enterprise integrating the R&D, production, marketing, distribution as well as import & export, Zhifei mainly engages in the production of vaccines for human use, and always attached great importance to R&D progress. In this respect, Zhifei has established a professional R&D team of more than 800 peoples, and has participated in more than 40 major projects.

At present, Zhifei established 8 R&D matrices for disease prevention, including meningitis vaccines, pneumococcal vaccines, gastrointestinal virus vaccines, tuberculosis products, combination vaccines, emerging infectious diseases vaccines, adult vaccines, and upgraded vaccines. Zhifei also established 9 major technology platforms, including polysaccharide and conjugate technology, genetic recombinant technology, inactivation technology, combo and multi-valent technology, mRNA technology, novel adjuvant technology, human diploid cell technology, adenovirus vector technology, outer membrane vesicle (OMV) technology and other technology platforms.

Based upon the above strengths, Zhifei has successfully developed and launched various products on the market, including Recombinant Novel Coronavirus Vaccine (CHO Cell)，Recombinant Mycobacterium Tuberculosis Fusion Protein (C-TST, one of three global innovative TBST products), Hib Vaccine, Group ACYW₁₃₅ Meningococcal Polysaccharide Vaccine, Mycobacterium Vaccae for Injection, Meningococcal Group AC Polysaccharide Conjugate Vaccine, and other independently developed products. Products such as COVID-19 vaccines and ACYW135 Meningococcal vaccines manufactured by Zhifei have been exported to many countries and regions with more than 400 million doses used globally.

Meantime, Zhifei is the sole distribution partner with the vaccines of Merck Sharp & Dohme (MSD) and Recombinant Zoster vaccine (Shingrix) of GSK in China.

We look forward to march forward with partners from all over the world.